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Abstract: As a metalloproteinase specialized in releasing membrane-tethered proteins, A Disintegrin and A 
Metalloproteinase 17 (ADAM17), also known as Tumor necrosis factor-? Converting Enzyme (TACE) or less commonly 
CD156q, has received more than its share of attention. This is mainly because major contemporary pathologies like 
cancer, inflammatory and vascular diseases seem to be connected to its cleavage abilities. The involvement in such a 
broad spectrum of diseases is due to the large variety of substrates that ADAM17 is able to cut. ADAM17 can activate 
growth factors or inactivate receptors by shedding their extracellular domain from the cell membrane. Similarly, it can 
detach cells by cleaving cell adhesion molecules. Some of these proteolytic events are part of cleavage cascades known as 
Regulated Intramembrane Proteolysis and lead to intracellular signaling. It is therefore clear that ADAM17 literally 
fulfills a key role in diverse processes and pathologies, making it a prime target for developing therapies. Here we review 
the role of ADAM17 in health and disease and highlight the problems to overcome for ADAM17 to mature towards a 
therapeutically valuable target. 
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STRUCTURE 
 As the other ADAMs, ADAM17 is a modular type I 
protein that contains, in addition to the signal peptide, four 
functionally distinct extracellular domains followed by a 
transmembrane region and a cytoplasmic tail (Fig. 1) [1]. 
Prodomain 
 The prodomain keeps ADAM17 in an inactive state by 
blocking the metalloproteinase catalytic site. It has been re-
cently shown that the so called "cysteine switch" mechanism, 
that operates in many Matrix Metalloproteinases (MMPs) 
and ADAMs and consists of the coordination of the zinc ion 
by a cysteine located in the prodomain, is not necessary for 
keeping the precursor of ADAM17 in an inactive state [2]. It 
is removed by furin-like proprotein convertases in the trans-
Golgi compartment by cleavage at the consensus RX(R/K)R 
motif [3, 4]. The synthesis and purification of isolated pro-
domains from different ADAMs, including ADAM17, has 
confirmed that they can act as potent, selective inhibitors of 
the mature active forms of the metalloproteinase [5-7].  
 In addition to its inhibitory function, the prodomain also 
acts as a chaperone and protects the enzyme from degrada-
tion during transport through the secretory pathway [2].  
Metalloproteinase Domain 
 Out of the 25 human ADAMs, 13, including ADAM17, 
bear the characteristic reprolysin-type active site (HEXGH- 
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XXGXXHD) involved in coordinating the zinc atom [8]. 
This Zn-binding motif is followed by the ‘‘Met turn”, which 
is the signature of the enzymes belonging to the Metzincin 
clan [9].  
 The metalloproteinase domain of ADAM17 is function-
ally the most relevant. Knockout mice expressing a deleted 
form of ADAM17 lacking the Zn binding domain display a 
severe phenotype characterized by the death of most em-
bryos around birth [10] that is similar to that of animals lack-
ing the entire gene [11]. 
 How ADAM17 recognizes its many substrates is still far 
from clear. The primary sequence of the cleavage site does 
not seem to play a determinant role. In fact, cleavage sites 
differ between different ADAM17 substrates and there are 
no similarities in the surrounding sequences. Moreover, 
mutagenesis of residues around or even at the cleavage site 
do not prevent the shedding of some ADAM17 substrates 
[12-15]. However, using a Biotin-LAQA-P1'-P2'-SSK(DNP)-
NH2 template, based on the cleavage site found in the proin-
flammatory cytokine pro-Tumor Necrosis Factor ? (pro-
TNF?), recombinant TACE was shown to prefer lipophilic 
amino acids at the P1' position and basic amino acids at the 
P2' position [16, 17]. 
 Evidence suggests that the distance from the membrane 
may be important for determining the cleavage, since this 
almost invariably occurs at 10-15 amino acids from the 
plasma membrane. For example, deletion of more than 10 
amino acids from the extracellular juxtamembrane region of 
proTNF?, blocked the release of soluble TNF? [18]. How-
ever, additional features have been suggested to play a role 
in recognition of the juxtamembrane regions to be cleaved, 
such as the tertiary structure of the extracellular domain [12].  
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 It has also been suggested that the cysteine-rich domain 
of ADAM17 specifically interacts with certain substrates 
(see below). However, to date, the number of such substrates 
is very low and, for the recognition of most ADAM17 sub-
strates, the participation the cysteine-rich domain has not 
been substantiated. 
Disintegrin Domain 
 Because of its high degree of homology, the disintegrin 
domain of ADAMs was named after the snake venom 
disintegrins, which bind specific integrins [19]. Integrins are 
heterodimeric receptors consisting of ? and ? chains with a 
ligand-binding extracellular domain and a short cytoplasmic 
tail. They support cell migration by providing the connection 
between the cell cytoskeleton and the extracellular matrix. In 
addition to a structural role, they also trigger signaling path-
ways (reviewed in [20]). The binding to extracellular ligands 
initiates intracellular signaling that, in turn, regulates differ-
ent aspects of the cellular behavior such as cell adhesion, 
cytoskeleton reorganization and cell polarity [21]. 
 As is the case for other ADAMs, the interaction of 
ADAM17 with integrins is promiscuous: ADAM17 interacts 
with different integrins and a given integrin interacts with 
different ADAMs, including ADAM17. Although the func- 
tional outcome of ADAMs and integrins is not clear [22], it 
has been shown that ADAM17 impairs cell migration 
through binding to ?5?1, one of its cognate integrins [23].  
Cysteine-Rich Domain 
 The Cys-rich domain is regarded as a regulatory domain 
that acts at different levels. It is important for the recognition 
of particular substrates [24] as well as for the maturation of 
ADAM17 [25]. Modulation of disulfide bonds in the cys-
teine-rich domain affects L-selectin shedding. Using a cell-
based ADAM17 reconstitution assay, Wang and colleagues 
demonstrated that the cysteine-X-X-cysteine motifs are criti-
cal for L-selectin cleavage [26]. Similarly, analysis of 
ADAM17 deletion constructs shows that the Cys-rich do-
main is required for the shedding of Interleukin-1 Receptor-
II shedding, but not for the shedding of proTNF? or the 
TNF? receptor, p75TNF [24]. In line with these findings, the 
Cys-rich domain of ADAM10 seems to participate in the 
recognition and cleavage of Ephrin A5 [27]. Ephrins are cell-
associated ligands for Eph tyrosine kinase receptors and sig-
nal repulsion of adjacent cells upon receptor binding [28]. 
After binding to its cognate receptor, the Ephrin-A5 ligand is 
cleaved in trans by ADAM10 [29]. This cleavage event de-
pends on the formation of a de novo high affinity binding 
site for the Cys-rich domain of ADAM10 by the Ephrin A5-
receptor complex, properly positioning ADAM10 for cleav-
age. It remains to be established if other ADAMs, including 
ADAM17, use a similar mechanism to recognize certain 
substrates. 
 The importance of the Cys-rich domain in the maturation 
of ADAM17 has been unveiled characterizing the CHO-M2 
cell line, that bears a mutation in a cysteine, located in the 
Cys-rich domain [30]. Functional analyses confirmed that 
Cys600 was indispensable for the maturation and activity of 
ADAM17 [3]. 
Cytoplasmic Domain 
 The 130 amino acid long cytoplasmic domain binds to a 
variety of intracellular signaling molecules including Protein 
Kinase C (PKC), Extracellular signal-regulated kinase 
(ERK) and mitotic arrest deficient 2 (MAD2), but the exact 
functional role of these interactions is still largely unknown 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Schematic showing the different domains of ADAM17 and the functions that they fulfill. See text for details. 
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(reviewed in [8]). Although intracellular signals can influence 
ADAM17 catalytic activity, this seems to be independent 
from the cytoplasmic domain [24] and is probably mediated 
through other transmembrane proteins. 
 It has recently been shown that a proline-rich stretch in 
the cytoplasmic domain of ADAM10, the closest relative to 
ADAM17, is important for the correct basolateral position-
ing of ADAM10 in polarized epithelial cells, resulting in E-
cadherin cleavage and promoting cell migration upon correct 
localization [31]. Presently, the identity of the intracellular 
protein that controls this process is not clear, though Synapse 
Associated Protein-97 (SAP97) interacts with this region of 
ADAM10 and is responsible for correct insertion of 
ADAM10 in synaptic membranes [32]. Interestingly, SAP97 
also interacts with the cytoplasmic domain region of 
ADAM17, via the third PDZ domain of SAP97 [33]. 
 Intriguingly, even though the cytoplasmic domain inter-
acts with proteins and can be phosphorylated in response to 
phorbol ester treatment, that also induces shedding, its dele-
tion has apparently no effects on ADAM17 catalytic activity 
[24]. This observation is even more puzzling considering 
that the cytoplasmic domain contains a potential tyrosine 
phosphorylation site in a Src homology 2 domain binding 
site, (KKLDKQYESL705), as well as a potential Src homol-
ogy 3 domain binding site, (PAPQTPGR738). 
THE DEGRADOME OF ADAM17 
 The discovery of new ADAM17 substrates has been 
continuous during the last decade and, currently, there are 
over fifty known substrates (Table 1). The substrates of 
ADAM17 are functionally and structurally heterogeneous 
and include membrane anchored growth factors and cyto- 
kines, receptors, cell adhesion molecules and ectoenzymes. 
In many instances the cleavage by ADAM17 has been 
shown to regulate the function of a given substrate leading to 
activation, inactivation or modulation of the activity 
(reviewed in [34, 35]). 
Membrane-Anchored Ligands 
 Many soluble growth factors and cytokines are synthe-
sized as transmembrane proteins (see Table 1). The shedding 
of the extracelluar domain of membrane-anchored growth 
factors and cytokines by ADAM17 constitutes a clear exam-
ple of how metalloproteinases control signaling pathways. 
Evolutionary, this system is widespread and ADAM17 
orthologs can be found in mouse, zebra fish, roundworm and 
the fruit fly. The main advantage of this regulatory mecha-
nism is that the response to environmental cues can be swift, 
rapidly switching a pathway either on or off, and independ-
ent from the slower transcription-translation system. For 
example, the release of transforming growth factor- alpha 
(TGF-?), a ligand for the Epidermal Growth Factor Receptor 
(EGFR), constitutes a straightforward activation process, 
because the membrane-bound proTGF-? is largely inactive 
[36]. A number of other EGFR ligands are similarly inactive 
when membrane anchored (reviewed in [8]). 
 In the case of TNF-?, the ADAM17 cleavage results in a 
transition between two active forms with different properties 
[37]. The human carcinoma cell line Colo205, is resistant to 
the soluble TNF-?, but sensitive to membrane-associated 
proTNF-? [38]. Furthermore, mice expressing an uncleav- 
able form of proTNF-? are unable to undergo septic shock, 
demonstrating the fundamental role proteolytic cleavage has 
in this pathological process [39]. Similarly, the EGF-like 
ligands known as neuregulins, are fully active even when 
membrane bound and cleavage by ADAM17 represents the 
conversion of a physically restricted growth factor into a 
diffusible isoform [40].  
Receptors 
 It is not surprising that, in addition to ligands, the 
ADAM17 degradome includes many receptors, since the 
cleavage of this type of molecule offers an additional way to 
regulate the response of the cell to growth factors and cyto- 
kines. Not only will a shed receptor be unable to transmit 
signals to the cell, but it can act as a ligand-sequestring 
scavenger. This is nicely illustrated by the shedding of the 
receptors for TNF-? by ADAM17 and the subsequent seque- 
stering of TNF-? by the soluble receptors, which prevent the 
binding of the cytokine to the full-length receptors [37].  
 In contrast to the negative impact on TNF-? signaling, 
ADAM17 can be an activator of certain receptors. The well-
studied case of Notch, a receptor that determines the 
developmental fates of mainly neuronal and hematopoietic 
cell populations, constitutes an excellent example of receptor 
activation by proteolysis [41]. Following ligand binding, 
ADAM17 releases the extracellular domain of Notch while 
the so-called “stub”, consisting of the transmembrane and 
cytoplasmic domain, stays behind in the membrane. This 
stub now becomes a substrate for Regulated Intramembrane 
Proteolysis (RIP) by ?-secretase. In turn, the released intra- 
cellular domain of Notch can translocate to the nucleus where 
it regulates the expression of its target genes [42]. Other 
receptors cleaved by ADAM17 such as ErbB4 [43] and the 
cell adhesion molecules N-cadherin [44] and CD44 [45], 
have been shown to signal through a similar mechanism. 
Cell Adhesion Molecules  
 Highlighting its importance in the regulation of cell-cell 
interactions, ADAM17 was shown to act on a large group of 
cell adhesion molecules (Table 1) [10, 46-51]. An obvious 
effect of the shedding of cell adhesion molecules is the 
weakening of cell-cell interactions (reviewed in [22]). In 
addition, the shedding of certain cell adhesion proteins is 
relevant in signal transduction. As in the case of Notch, the 
shedding of CD44 by ADAM17 and other metallopro- 
teinases, is followed by a RIP event, that releases the 
intracellular domain (ICD) of CD44. The ICD translocates to 
the nucleus, where it regulates the transcription of target 
genes [52].  
ADAM17 DYSFUNCTION AND DISEASE 
 Despite the remarkably large number of ADAM17 
substrates identified during the last decade (see Table 1), to 
date, most of the proposed pathological roles of the 
metalloproteinase are related to just a few, namely, TNF-?, 
the ligands of the EGFR and the Amyloid Precursor Protein 
(APP) (Fig. 2). However, given the central role of these 
molecules in many biological processes, the number of 
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diseases in which ADAM17 has been suggested as a 
therapeutic target has grown exponentially in the last years. 
 
Table 1. ADAM17 Substrates  
Substrate Reference 
Cytokines and Growth Factors 
proTNF-? (pro-tumor necrosis factor-?) [150, 62] 
proTGF-? (pro-transforming growth factor-?) [10] 
proAR (pro-amphiregulin) [151] 
proBTC (pro-betacellulin) [50, 152, 
153] 
proEPR (pro-epiregulin) [152] 
proEPG (pro-epigen) [154] 
proNRG?-2C (pro-neuregulin-?-2C, Heregulin) [155] 
proHB-EGF (pro-heparin-binding epidermal growth factor) [156] 
pref-1 (preadipocyte factor 1) [157] 
Fractalkine (CX3CL1) [158] 
SEMA4D (semaphorin 4D) [159] 
LAG3 (lymphocyte activation gen 3) [160] 
Dll1 (delta-like 1) [161] 
Kit ligand-1 and -2  [162] 
MICA (MHC-class I-related chain A/B)  [163]  
Receptors  
p75 TNF-? RII (tumor necrosis factor-? receptor II) [10] 
p55 TNF-? RI (tumor necrosis factor-? receptor I) [24] 
p75NTR (neurotrophin receptor) [164] 
IL-6R? (interleukine-6 receptor-?) [165] 
IL-1RII (interleukine-1 receptor type II) [24] 
IL-15R? (interleukine-15 receptor ?) [166] 
TrkA neurotrophin receptor  [167] 
GHR (growth hormone receptor) [168] 
M-CSFR (macrophage colony stimulating factor receptor) [169] 
SorLA receptor (Vps10-p domain receptor)  [170] 
 LDL receptor [170] 
AXL receptor [170] 
PTP-LAR (protein tyrosine phosphatase LAR receptor) [171] 
EPCR (endothelial protein C receptor) [172] 
ACE2/ SARS-CoV Receptor  [16] 
NPR (neuronal pentraxin receptor)  [173] 
HER4 [174] 
Notch [175] 
CD30 [176] 
CD40 [177] 
GPIb? (glycoprotein Ib-?) [178] 
Adhesion molecules  
ICAM-1 (intercellular adhesion molecule-1) [51] 
VCAM-1 (vascular cell adhesion molecule-1) [49] 
NCAM (neural cell adhesion molecule) [179] 
ALCAM (activated leukocyte cell adhesion molecule) [46] 
L1-CAM  [180] 
RA175/SynCAM1 [181] 
Dsg-2 (desmoglein 2) [46] 
L-selectin [10] 
Collagen XVII [48] 
Nectin-4 [47] 
CD44 [50] 
Other molecules  
APP (amyloid precursor protein) [182] 
APLP2 (APP-like protein 2) [183] 
Ebola virus glycoprotein GP [184] 
Carbonic anhydrase IX [185] 
Cellular prion protein [186] 
Klotho  [187] 
MUC-1 [188] 
C4.4A [189] 
 
 The ligands of the EGFR are synthesized as type I 
transmembrane molecules that can be proteolytically activa- 
ted by ADAMs in general, but particularly by ADAM17 [8]. 
This makes ADAM17 a key therapeutical target for diseases 
where dysregulation of the EGFR signaling pathway plays a 
pathogenic role such as cancer. 
 The dysregulation of TNF-? is connected to several 
inflammatory disorders, including rheumatoid arthritis (RA) 
[53] and osteoarthritis [54], inflammatory bowel disease 
(IBD) [55], stroke [56], endotoxic shock [57] and multiple 
sclerosis (MS) [58]. Although other proteinases have been 
shown to be proteolyticaly active towards the membrane-
anchored proTNF-? [59-61], ADAM17 appears to be the 
most efficient in vivo [62]. For this reason, ADAM17 is 
considered an effective therapeutic target in TNF-? mediated 
disorders. 
 The APP protein is the precursor for the amyloid beta 
(A?) peptide, that when produced at high levels, accumulates 
in the form of amyloid plaques in the brain of Alzheimer’s 
disease patients [63]. The A? is formed by the sequencial 
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cleavage by the, so-called ?- and ?-secretases [64]. A third 
secretase, alpha-secretase, cleaves withing the A? peptide 
precludig its production. ADAM17 seems to be endowed 
with ?-secreatese activity [65, 66] and, thus, its activation 
has been suggested as a therapeutic approach in the treatment 
of Alzheimer’s disease [67]. 
 Although to date only these ADAM17 substrates seem to 
be relevant in human disease, it cannot be discarded that the 
number of disease-relevant transmembrane proteins cleaved 
by ADAM17 could expand even more in the near future. 
Cancer 
 The EGFR (also known as HER1 receptor or ErbB1), is 
the prototype of a family that includes three additional mem-
bers: HER2 (also known as Neu or ErbB2), HER3 and 
HER4 (also known as ErbB3 and ErbB4, respectively) [68]. 
Upon ligand binding, the receptors undergo homo- or hetero-
oligomerization and activation. Activated HER receptors 
transduce signals through a plethora of intracellular factors 
that, ultimately, regulate the expression of groups of genes 
that control cellular proliferation, migration, adhesion, dif-
ferentiation and apoptosis [68]. 
 The ligands for the HER receptors are synthesized as 
transmembrane molecules that are cleaved by ADAM17 and 
ADAM10 and perhaps other ADAMs, particularly when 
overexpressed [8]. In several instances cleavage activates the 
ligand (see, for example [36]), that, as a soluble form can 
bind and activate the HER receptors.  
 The clearly established involvement of HER receptors in 
cancer progression has led to the implementation of different 
therapeutic strategies including monoclonal antibodies 
targeting the ectodomain of the receptors and tyrosine kinase 
inhibitors [69]. In principle, inhibition of ADAM17 and, 
hence, immobilization of several EGFR ligands, could 
complement current anti-EGFR tumor therapies, particularly 
when ADAM17 is overactivated. This hypothesis has lead to 
the characterization of the role of ADAM17 in different 
types of tumors.  
Lung Cancer 
 The leading cause of cancer-related death is lung 
carcinoma, a devastating disease responsible each year for 
1.3 million deaths (WHO (2004). Deaths by cause, sex and 
mortality stratum). Histologically, lung cancers are classified 
as non-small-cell lung cancer (NSCLC), adenocarcinoma, 
squamous-cell carcinoma, or large-cell undifferentiated 
carcinoma [70]. The EGFR pathway is overactivated in most 
patients with NSCLC, and, consistent with a causal role of 
this overactivation in the pathogenesis of the disease, an 
inhibitor of the tyrosine kinase of the EGFR (Gefitinb) has 
shown efficacy in a large-scale clinical trial for NSCLC. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Schematic showing the types of diseases in which ADAM17 is involved, through the cleavage of EGF-like ligands, proTNF-alpha 
and betaAPP. 
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Unfortunately, due to primary or acquired resistance to the 
drug , the overall response was much lower than expected 
[71].  
 One of the mechanisms of resistance to Gefitinib, 
involves the autocrine production of soluble HER receptor 
ligands mediated, at least in part, by ADAM17 [72]. In fact, 
ADAM17 protein levels are upregulated in the majority of 
human lung cancer samples analyzed and the levels of 
ADAM17 correlate with the activation of HER3 [72]. 
Apparently, the increased levels of ADAM17 result in an 
increased production of soluble heregulin, an ADAM17 
substrate and a ligand for HER3. High levels of soluble 
heregulin leads to HER3 activation, which is unaffected by 
gefitinib, and subsequent promotion of cell growth, 
migration and resistance to apoptosis [72]. Consistent with 
these results, gefitinib insensitivity correlates with heregulin 
expression and treatment of resistant cells with INCB3619, 
an inhibitor of ADAM17 and ADAM10, blocks heregulin 
release and sensitizes a Gefitinib-resistant human NSCLC 
cell line to Gefitinib treatment [72]. This study shows that 
ADAM17 inhibitors may impair one of the mechanisms of 
resistance to tyrosine kinase inhibitors targeting the EGFR 
and indicate that the combinantion of tyrosine kinase 
inhibitors and inhibitors of ADAM17 may be an effective 
way to treat some lung cancers. 
Breast Cancer 
 Breast cancer is the most frequent malignancy among 
women in the industrialized countries. There are nearly 1 
million new cases per year, worldwide (WHO World Cancer 
Report (June 2003)). 
 Different components of the EGFR pathway, such as 
HER2, are overactivated and play a causal role in breast 
cancer progression [73]. ADAM17 is frequently overex-
pressed in breast cancers [36] and its overexpression is asso-
ciated with tumor progression and metastasis [74]. Appar-
ently, the overexpression of ADAM17 is due to transcrip-
tional [74] as well as post-transcriptional mechanisms [75]. 
 Genetic or biochemical inhibition of ADAM17 leads to 
the prevention of the shedding of EGFR ligands in different 
cells, including cells derive from breast tumors [36, 74, 76]. 
Blocking the shedding of proTGF-? results in the inactiva- 
tion of the EGFR, indicating that ADAM17 inhibitors can be 
useful to target the EGFR pathway also in mammary tumors.  
Other Cancers 
 In human colorectal tumors, ADAM17 levels and activity 
are elevated compared to healthy control tissue [77]. ADAM- 
17 protein expression is also higher in pancreatic ductal 
carcinoma [78], prostate cancer [79] and ovarian cancer [80] 
and increased ADAM17 protein expression correlated with 
disease severity in oral squamous cell carcinoma [81].  
 In these tumors the overexpression of ADAM17 tends to 
correlate with the activation of the EGFR pathway. Thus, 
inhibitors of the metalloproteinase would block EGFR 
signaling and could be therapeutic alone or in combination 
with other anti-EGFR drugs. Different experiments support 
this hypothesis. Nude mice injected with oral squamous 
carcinoma cells had slower tumor growth when treated with 
the ADAM17/ADAM10 inhibitor INCB3619 [82]. RNAi 
suppression of ADAM17 in renal carcinoma cells led to 
decreased cell proliferation [83]. Similarly, treatment of U87 
human brain tumor cells with ADAM17-specific RNAi led 
to decreased invasion [84]. 
Inflammatory Diseases 
Rheumatoid Arthritis 
 Rheumatoid arthritis is an autoimmune disease which 
affects approximately 1% of the world’s population. It is 
characterized by chronic systemic inflammation [85]. 
Rheumatoid joints contain inflammatory infiltrates that 
spread from the synovia [86]. Eventually, this synovitis leads 
to the degradation of the joint surface, resulting in loss of 
function. 
 The TNF-? signaling pathway is overactivated in the 
inflammatory infiltrates and induces the production of the 
degrading enzymes that contribute to the erosion of cartilage 
and bone [87]. Human RA cartilage displays upregulated 
ADAM17 mRNA expression [88], indicating that the meta- 
lloproteinase is responsible, at least in part, for the over- 
activation of the TNF-? pathway. In turn, chronic hypoxia, 
one of hallmarks of rheumatoid arthritis seems to contribute 
to the upregulation of ADAM17. It has been recently shown 
that this low oxygen condition, along with TNF-? itself, 
upregulates the transcription of ADAM17, through the tran-
scription factor hypoxia inducible factor HIF-1, in synovial 
cells [89]. Confirming the importance of this positive feed-
back loop in the pathology of RA, there is a positive correla-
tion between ADAM17 and HIF-1 protein levels in RA 
synovium [89]. 
 Neutralization of the TNF-? signaling pathway, by 
blocking the interaction of the cytokine with its cognate re-
ceptors, has been demonstrated as a feasible approach to 
treating RA. For example, positive results have been re-
ported using etanercept, a TNF receptor p75 IgGFc fusion 
protein [90]. 
 Since ADAM17 cleaves proTNF-alpha to yield a soluble 
form, inhibition of this enzyme is a feasible therapeutic 
intervention (review see [91]). This hypothesis has been 
proven in different animal models. Mice immunized against 
collagen and treated with LPS (lipopolysaccharides) develop 
RA symptoms. In this model, inhibitors of ADAM17 show 
efficacy, both prophylactically and therapeutically [92]. 
Confirming the therapeutic value of ADAM17 inhibitors, 
their effect is comparable, or even higher than that of drugs 
directed direclty against TNF-? [92]. 
 The effect of ADAM17 inhibitors has also been analyzed 
in other frequently used RA models such as collagen-
induced arthritis (CIA) in rats and mice [93]. DPC333, a 
selective ADAM17 inhibitor, suppressed the maximal res- 
ponse by 50% in the CIA model [94]. Furthermore, the 
ADAM17 inhibitor GW-3333 was shown to be exceptionally 
potent and long lasting in a rat arthritis model [95]. 
Inflammatory Bowel Disease 
 Ulcerative colitis and Crohn’s disease, collectively 
known as inflammatory bowel disease, are major causes of 
lifetime morbidity [96]. Although these diseases are often 
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differentiated clinically, they share many characteristics 
including an exacerbated mucosal inflammatory response 
caused by overactivation of TNF-? signaling [97]. Increased 
TNF-? signaling leads the upregulation of inducible nitric 
oxide synthase (iNOS) which has also been implicated in 
IBD (reviewed in [98]). ADAM17 protein levels are 
increased in mucosal biopsies from patients with ulcerative 
colitis but not in Crohn’s disease, indicating that it plays a 
pathogenic role in the former disease. 
 Neutralizing antibodies against TNF-? are effective in 
treating IBD [99]; however, antigenicity and high cost have 
raised interest in alternative strategies to block TNF-? 
signalling, such as inhibition of ADAM17.  
 Colon et al. showed that the colitis induced in rats by 
trinitrobenzene sulphonic acid (TNBS) is characterized by an 
increase in the levels of soluble TNF-alpha, ADAM17 and 
iNOS [100]. The ADAM17 inhibitor BB1101 blocked 
TNBS-induced increase in ADAM17 activity, TNF-? release 
and iNOS expression. Thus, inhibitors of ADAM17 may 
prove useful as a therapeutic means in IBD, in particular for 
patients suffering ulcerative colitis.  
Stroke 
 Stroke, or cerebrovascular accident, often results in per- 
manent disability and is the number two cause of mortality 
worldwide [101]. Moreover, the incidence of stroke is likely 
going to increase due to population ageing [102]. Stroke can 
be the result of either restricted/blocked bloodflow to part of 
the brain, or hemorhage, both resulting in neuronal necrosis. 
Despite the complexity and heterogeneity of the disease, 
accumulating evidence shows that inflammation plays a 
crucial role [103]. Thus, it is not surprising that TNF-?, and 
therefore ADAM17, are considered therapeutic targets for 
the treatment of stroke. Confirming this notion, a selective 
small molecule inhibitor of ADAM17 (DPH-067517), sup- 
presses ischemia-induced increase in soluble TNF-? and 
ameliorates ischemic stroke in rats [104]. Similarly, treat- 
ment of a rat model of reperfusion injury with the ADAM17 
inhibitor Tissue Inhibitor of Metalloproteinase-3 (TIMP3) 
diminished the diseases severity compared with untreated 
rats [105]. 
Other Inflammatory Diseases 
 Aberrant ADAM17 expression is also connected to other 
inflammatory disorders such as peritonitis [106], polymyo- 
sitis, dermatomyositis and inclusion body myositis [107]. In 
addition, ADAM17 protein levels were increased in gingival 
crevicular fluid taken from patients with periodontitis com- 
pared to that taken from healthy controls [108] and in pla- 
cental tissue from pregnancies complicated by chorio- 
amnionitis [109]. 
 Blocking TNF-? signaling by using Etanercept is a 
current treatment for psoriasis. ELISA analysis on blood 
taken from psoriasis patients showed elevated ADAM17 
protein expression [110] and treatment of a mouse model of 
epidermal hyperplasia with compound 1b, an MMP/ADAM- 
17 inhibitor, led to a reduction in the severity of psoriasis in 
these mice [111]. 
 Finally, increased ADAM17 expression is reported in 
blood vessels, macrophages and astrocytes in active lesions 
with evidence of recent myelin breakdown from MS patients 
[112]. 
Cardiovascular Diseases 
 Animal models suggest a role for ADAM17 in the devel-
opment of the heart, likely through the cleavage of EGF-like 
ligands. For example, ADAM17 knockout mice show 
enlarged stenotic semilunar and atrioventricular heart valves 
suggestive of defective valvulogenesis [113]. Consistently, a 
number of cardiovascular disorders have been related to 
ADAM17 overexpression. Myocardial tissue from patients 
with myocarditis, hypertrophic obstructive cardiomyopathy 
and dilated cardiomyopathy displayed higher ADAM17 
protein levels compared with healthy controls [114]. Like- 
wise, ADAM17 protein expression was raised in arterial 
tissue from patients with atherosclerosis [115] and abdominal 
aortic aneurysm [116]. Peripheral Blood Mononuclear Cells 
taken from patients with heart failure also showed increased 
ADAM17 protein expression [116]. Finally, a positive 
correlation exists between elevated ADAM17 protein levels 
in aortic tissue biopsies and severity of acute myocardial 
infarction [117].  
Chronic Renal Diseases  
 Independently of how they originate, most human kidney 
diseases are characterized by an initial damage, followed by 
progression of renal lesions developing towards complete 
parenchymal destruction and renal failure [118]. 
 Although, the mechanisms of progression remains 
unclear Angiotensin II (AngII), seems to be involved since 
chronic AngII infusion leads to renal lesions in mice [119]. 
Genetic evidence indicates the participation of the EGFR 
pathway in the AngII-induced renal disease: mice overex- 
pressing a dominant negative isoform of the EGFR are 
protected from these induced renal lesions [120]. Further- 
more, AngII-induced lesions were substantially reduced in 
mice lacking TGF-? [120]. AngII causes induction and 
redistribution of ADAM17 to the apical membranes of distal 
renal tubules, where it is able to cleave the proTGF-? 
precursor so the soluble ligand can activate the receptor 
[120]. 
 Pharmacologic inhibition of ADAM17 prevents renal 
deterioration, corroborating the role of the EGFR in the 
pathology of the disease and pointing to ADAM17 inhibitors 
as a new therapeutic strategy for preventing progression of 
chronic renal diseases [120]. 
Respiratory Diseases 
 ADAM17 expression is elevated in peripheral-blood 
monocytes from refractory asthma patients [121] and in the 
epithelial lining fluid of patients with pneumonia. Green and 
coworkers showed that ADAM17 has a role in regulating the 
local inflammatory response in community-acquired pneu- 
monia through modulation of inflammatory cytokine levels 
[122]. 
 ADAM17 protein is also overexpressed in the lungs of 
Wistar rats challenged with passive smoking and intra- 
tracheal instillation of LPS (a model for chronic obstructive 
pulmonary disorder, COPD). TNF-? and ErbB3 are known 
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to be involved in the pathogenesis of COPD and so the 
contribution of ADAM17 to the disease seems to be two 
fold: through the activation of the TNF-? and ErbB3 
pathways and, thus, inhibition of the metalloprotease seems 
to be a feasible therapeutic approach [123]. 
Metabolic Diseases 
 Compared to healty mice, diabetic mice heterozygous for 
the insulin receptor express lower levels of TIMP3, and 
inhibitor of ADAM17, and, consequently, higher ADAM17 
activity. On the other hand, treatment with the ADAM17 
inhibitor TAPI-1 causes an increase in insulin sensitivity and 
a decrease in hyperglycemia and vascular inflammation, 
suggesting that ADAM17 overactivity may cause diabetes 
and vascular inflammation [124]. Confirming this hypo- 
thesis, rats maintained on a fructose-rich diet for 6 weeks 
developed insulin resistance, but treatment with the 
ADAM17 inhibitor KB-R7785 reduced the severity of the 
disease [125]. 
 ADAM17 also seems to be involved in diet-related 
diseases. Obesity caused by a high-fat diet in wild type mice 
leads to an increase in the expression of ADAM17 [126]. 
Heterozygous ADAM17+/- mice fed a high fat diet were 
relatively protected from obesity and insulin-resistance 
compared to their wild-type littermates [127]. Increased 
ADAM17 expression is also detected in monocytes in re-
sponse to LDL from diabetic patients versus controls [128]. 
Mice fed with a fat-free, high carbohydrate diet developed 
severe fatty liver infiltration. The severity of this condition 
was decreased upon treatment with the MMP inhibitor 
Marimastat, indication that ADAM17 is also involved in the 
pathogenesis of fatty liver [129]. 
Alzheimer’s Disease 
 To our knowledge, the only pathology in which an 
increased ADAM17 activity has been suggested to be 
favourable is Alzheimer’s disease. 
 The deposition of the A? peptide in the brain is touted to 
play a causal role in the pathogenesis of the disease [130]. 
A? is generated from a transmembrane protein named APP 
through the cleavage by ?- and ?-secretases. Alternatively, 
APP may be cleaved by ADAM17 and ADAM10, which are 
also known as ?-secretases. The cleavage by ADAMs takes 
place within the region of APP that corresponds to A? and, 
thus, prevents the generation of the amiloidogenic peptide. 
 The feasibility of a therapeutic strategy based on the acti-
vation of metalloproteinases with alpha-secretase activity has 
been proven in animal models. The overexpression of func-
tional ADAM10 in neurons of transgenic mice also overex-
pressing human APP leads to increased production of 
APPs? (the soluble ?-secretase shedded APP fragment) and 
reduced amyloid plaque formation and overall cognitive 
deficits [131]. Similarly, it has been proposed that the 
upregulation of ADAM17 is a promising therapeutic 
approach for treating Alzheimer’s disease [132]. 
Other Diseases 
 ADAM17 protein overexpression is also linked with a 
variety of diseases not falling into the above categories. 
ADAM17 was elevated in endometriosis tissue compared to 
healthy endometrium [133]. ADAM17 is overexpressed at 
the site of injury of the sciatic nerve in a rat model of sciatic 
neuropathy as shown by immunohistochemistry [134]. 
Western blot detected an increase in ADAM17 protein ex- 
pression in the brain cortex of rats subjected to immobiliza- 
tion stress [135]. Overexpression of ADAM17 protein was 
also detected in Peripheral Blood Mononuclear Cells from 
patients with systemic scleroderma [136] and in sural nerve 
biopsies of patients suffering from Guillain-Barre syndrome 
[137]. In addition, immunohistochemical analysis of nerve 
biopsies from leprosy patients showed an increase in 
ADAM17 protein expression compared with normal tissue 
[138].  
 Inhibition of ADAM17 also indicates its participation in 
additional diseases. Treatment with the ADAM17 inhibitor 
BB3103 protected rats against mucosal injury induced by 
aspirin administration which is used as a model for peptic 
ulcer [139]. Similarly, in a rat model for pneumococcal 
meningitis, disease severity was reduced by treating with the 
ADAM10/ADAM17 inhibitor BB1101 [140]. Finally, a role 
for ADAM17 in wound healing was suggested by a scratch-
wound model in human NCI-H292 human airway epithelial 
cells as the cells exhibited impaired wound repair when 
ADAM17 was suppressed by RNAi [141]. 
BLOCKING ADAM17 
 Leaving aside Alzheimer’s disease, the unusualy high 
number of diseases in which the overactivation of ADAM17 
has been suggested to play a role underscores the immense 
therapeutic potential of inhibitors. The availability of the 
structure of the proteolytic domain of ADAM17 [142] at a 
resolution of 1.7 Å, has allowed the development of 
numerous inhibitors (Table 2) with various degrees of speci- 
ficity. Some compounds block, in addition to ADAM17, 
closely related ADAMs and MMPs, while other seem to be 
highly specific. ADAM17 inhibitors are being assayed in 
different preclinical models of different diseases as well as in 
clinical trials, discussed below. 
Rheumatoid Arthritis 
 Initially, the lack of specificifity of metalloproteinase 
inhibitors was not considered a drawback. Since various 
MMPs contribute to joint destruction, in principle, ADAM17 
inhibitors with additional activity against MMPs could 
provide an advantage for the treatment of RA. Phase II 
clinical trials for RA with TMI-005 (Apratastat) was conduc- 
ted based on this hypothesis. However, this inhibitor showed 
low efficacy (Apratastat) or undesired side effects, likely due 
to the inhibition of multiple proteases. BMS-561392, an 
ADAM17 specific inhibitor demonstrated hepatotoxicity. 
This toxicity was thought to occur due to specific blocking 
of TNFR release by ADAM17, possibly posing a universal 
problem when inhibiting ADAM17 [91]. GI5402, a general 
metalloproteinase inhibitor that targets ADAM17, moderated 
the release of plasma-soluble TNF-? after intravenous 
injection of LPS in healthy individuals without producing the 
unwanted pro-inflammatory responses observed in in vitro 
experiments [143]. In view of these results, highly selective 
ADAM17 inhibitors are being developed to assure better 
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Table 2. Synthetic ADAM17 Inhibitors 
Inhibitor Target Stage of Development Disease Treatment Developed by Reference 
Analogues 14,15  
and 27 
ADAM17 Preclinical  Wyeth [147] 
BB-94 (batimastat) MMPs Discontinued  British Biotech [190] 
BB1101 MMPs Preclinical  AstraZeneca [191] 
BB3103 ADAM17/ADAM10 Preclinical  
British Biotech  
Pharmaceuticals 
[192] 
BMS-561392  
(DPC-333) 
ADAM17 Phase 1 Discontinued RA Bristol-Myers Squibb [193] 
BMS-566394 ADAM17 Preclinical  Bristol-Myers Squibb [91] 
CH-138 
ADAM17,  
Proteases, MMPs 
Discontinued  UCB [91] 
Compound 2o ADAM17 Preclinical  Bristol-Myers Squibb [148] 
Compound 4d ADAM17 Preclinical  Nippon Organon [194] 
Compound 4t ADAM17 Preclinical  Wyeth [195] 
Compound 51 ADAM17 Preclinical  Dupont Pharmaceuticals [196] 
Compound 5h and 5i ADAM17 Preclinical  Pfizer [197] 
Compound 5j ADAM17 Preclinical  Wyeth [198] 
Compound 5l ADAM17 Preclinical  Bristol-Myers Squibb [199] 
Compound 60 ADAM17 Preclinical  Wakunaga Pharmaceutical [200] 
Compound 7d ADAM17 Preclinical  Bristol-Myers Squibb, [201] 
Compound 7e,  
Cyclic Ether 50 
ADAM17 Preclinical  Abbott [202] 
Compound 8b ADAM17 Preclinical  Vertex [146] 
Compounds 11, 12, 
15a-b, 18 
ADAM17 Preclinical  Kaken Pharmaceutical [203] 
Compounds 41, 32, 62 ADAM17 Preclinical  Bristol-Myers Squibb [204] 
Compounds 64 and 65 ADAM17 Preclinical  Wyeth [205] 
CP-661,631  Preclinical  Pfizer [206] 
Derivative 7b,  
Compound 59 
ADAM17 Preclinical  Nippon Organon [200] 
DPC-A38088 ADAM17 Preclinical  Bristol-Myers Squibb 
http: 
//oasys2.confex.com/a
cs/228nm/techprogram
/P749069.HTM; [91] 
DPH-067517 ADAM17 Preclinical  Bristol-Myers Squibb [207] 
GI5402 (GI-245402,  
BB-2983) 
ADAM17, MMPs Phase I , Discontinued RA Glaxo Smithkline [143] 
GM6001 ADAM17, MMPs   Chemicon [208] 
GW-3333 ADAM17, MMPs 
Preclinical 
Discontinued 
 GlaxoSmithKline [209] 
GW280264X ADAM17/ADAM10 Preclinical  GlaxoSmithKline [210] 
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(Table 2) contd…. 
Inhibitor Target Stage of Development Disease Treatment Developed by Reference 
GW4459 ADAM17 Discontinued  Glaxo Smithkline [211] 
IK682 ADAM17 Preclinical  Bristol-Myers Squibb [212] 
IM491 ADAM17 Preclinical  Bristol-Myers Squibb [213] 
INCB3619 
ADAM17,  
ADA10, MMPs 
Preclinical NSCLC Incyte [72, 82] 
INCB4298 ADAM17 Preclinical  Incyte [72] 
INCB7839 ADAM10, ADAM17 Phase II Breast cancer Incyte [214] 
KB-R7785 
ADAM17,  
ADAM12, MMPs 
Preclinical  Nippon Organon [191] 
PKF242-484/ 
PKF241-466 
ADAM17, MMPs Preclinical  Novartis [215, 216] 
R-618 ADAM17 Phase I Discontinued  Hoffmann-La Roche [91] 
Ro 32-7315  Preclinical  Roche [217] 
TAPI-1 
ADAM17,  
ADAMs MMPs 
Preclinical  
Peptides International, 
Merck Biosciences, 
BIOMOL 
[218] 
TAPI-2 
ADAM17,  
ADAMs, MMPs 
Preclinical  
Peptides International, 
Merck Biosciences, 
BIOMOL 
[219-221] 
TMI-005 (Apratastat) ADAM17, MMPs Phase II Discontinued RA Wyeth [222] 
TMI-1 ADAM17, MMPs Preclinical RA Wyeth [223] 
TMI-2 ADAM17 Preclinical  Wyeth [224] 
W-3646 ADAM17 Discontinued  Wakanuga Pharmaceutical [91] 
WTACE2 ADAM17 Preclinical 
Polycystic kidney  
disease 
Wyeth [225] 
XL784 
ADAM10/ 
ADAM17/MMPs 
Phase II Discontinued 
Diabetic  
Nephro-pathy 
Exelixis 
[226] http: 
//www.exelixis.com/pi
peline_xl784.shtml#cd 
 
efficacy and less side-effects for the treatment of RA and 
other diseases where overactivation of ADAM17 plays a 
role. 
Renal Diseases 
 The ADAM10/ADAM17/MMP inhibitor XL784, de- 
signed to circumvent MMP1-associated musculoskeletal 
toxicity was well-tolerated in a Phase II clinical trial for 
diabetic nephropathy (NCT00312780). Unfortunately, the 
trial did not meet its primary endpoint of reducing pro- 
teinuria.  
Cancer 
 The failure of several metalloproteinase inhibitors with 
different levels of specificity (Table 2) in clinical trials led to 
the questioning of metalloproteases as therapeutic targets in 
cancer [144] and the subsequent realization that inhibition of 
certain metalloproteinases may in fact promote tumor pro-
gression [145]. Foreseeably, and taking into consideration 
the effectiveness of ADAM17 blockade in preclinical assays 
[72], the clinical efficacy of more selective metalloproteinase 
inhibitors will be tested in the future. Non-hydroxamate 
inhibitors include the thiol-based “compound 8b” [146], the 
pyrimidinetrione “compound 5l” [147] and the hydroxy- 
acetamide “compound 2o” [148]. In preclinical models 
INCB7839 showed single agent efficacy and synergism with 
other EGFR therapies and chemotherapy [149]. A Phase II 
trial in HER2 positive breast cancer has begun with 
INCB7839 and will be used to determine the its effective- 
ness in combination with Herceptin. 
Provisional Conclusions on the Use of Inhibitors 
 Several inhibitors of ADAM17 have failed during clini- 
cal trials because lack of efficacy and/or toxicity. The main 
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stumbling block in the further development of ADAM17 
inhibitors is the observation that promising in vitro 
nanomolar range inhibitors do not always show efficacy in 
vivo. This is not unique for ADAM17 inhibitors but rather a 
universal problem in the development of therapeutic com- 
pounds. The gap between in vitro and in vivo is due in part to 
pharmacokinetic factors coming into play when considering 
the whole organism and an incomplete understanding of the 
biology of ADAM17 inhibition. In addition, frequently 
molecules unrelated to the target, present in the plasma, are 
able to interfere with the inhibitory mechanism itself. 
Regarding toxicity, there is a clear need of more specific 
ADAM17 inhibitors. Higher specificity should help to 
diminish possible side effects and allow higher doses to be 
administered. Because of the observed toxicity effects in 
clinical trials, ADAM17 inhibitors are predicted to be of best 
use in cancer treatment. Since known and possible new 
undesirable effects, are more tolerated in view of a relatively 
short life cancer treatment in contrast to permanent RA care. 
The requirement of ADAM17 during EGFR activation, wich 
is a validated anti-cancer target, further advocates this 
possibility. 
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ABBREVIATIONS 
TACE  = Tumor necrosis factor-? Converting 
Enzyme 
ADAM = A Disintegrin and A Metalloproteinase 
MMP = Matrix Metalloproteinase 
(pro-)TNF-? = (pro-)Tumor Necrosis Factor-? 
PKC  = Protein Kinase C 
ERK  = Extracellular signal-Regulated Kinase 
MAD2 = Mitotic Arrest Deficient 2 
PDZ = post synaptic density protein (PSD95), 
Drosophila disc large tumor suppressor 
(DlgA), and zonula occludens-1 protein 
(zo-1) 
TGF-?  = Transforming Growth Factor-?  
EGF(R) = Epidermal Growth Factor (Receptor) 
RIP = Regulated Intramembrane Proteolysis 
ICD = IntraCellular Domain 
APP = Amyloid Precursor Protein 
RA = rheumatoid arthritis 
IBD = Inflammatory Bowel Disease 
MS = Multiple Sclerosis 
A? = Amyloid ? 
NSCLC = Non-Small-Cell Lung Cancer 
HIF = Hypoxia Inducible Factor 
LPS = LipoPolySaccharides 
AIA = Adjuvant-Induced Arthritis 
CIA = Collagen-Induced Arthritis 
iNOS = inducible Nitric Oxide Synthase 
TNBS = TriNitroBenzene Sulphonic acid 
TIMP = Tissue Inhibitor of Metalloproteinase 
AngII = Angiotensin II 
COPD = Chronic Obstructive Pulmonary Disorder 
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